|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
8 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Interest income on investments held in Trust Account | |||||
| Unrealized gain on investments held in Trust Account | |||||
| Impairment of amount due from related party | |||||
| Depreciation expense | |||||
| Stock-based compensation expense | |||||
| Non-cash interest expense | |||||
| Merger transaction costs | |||||
| Change in fair value of convertible promissory notes | |||||
| Loss on Series A Preferred Stock issuance | |||||
| Loss on issuance of commitment shares | |||||
| Change in fair value of warrants | |||||
| Amortization of right-of-use asset | |||||
| Change in operating assets and liabilities: | |||||
| Prepaid expenses and other assets | |||||
| Due from related party | |||||
| Due to affiliate | |||||
| Accounts payable and accrued expenses | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Operating lease liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Extension amount deposited into Trust Account | |||||
| Cash withdrawn from Trust Account in connection with redemption | |||||
| Purchases of property and equipment | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from note payable | |||||
| Redemption of ordinary shares | |||||
| Cash acquired in connection with the reverse recapitalization | |||||
| Gross proceeds | |||||
| Proceeds from issuance of Series C Preferred Stock | |||||
| Proceeds from loan agreement | |||||
| Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance | |||||
| Payments of deferred transaction costs | |||||
| Proceeds from issuance of convertible promissory notes | |||||
| Payment of offering costs associated with the sales agreement | |||||
| Proceeds from issuance of shares under the sales agreement, net of offering costs | |||||
| Capital contribution | |||||
| Net cash provided by financing activities | |||||
| Net Change in Cash | |||||
| Net (decrease) increase in cash | |||||
| Cash - beginning of period | |||||
| Cash - end of period | |||||
| Supplementary disclosure of noncash investing and financing activities: | |||||
| Change in value of Class A ordinary shares subject to redemption amount | |||||
| Sale of Class B shares to Investor | |||||
| Sale of warrants | |||||
| Reverse recapitalization transaction fees included in accrued expenses and other liabilities | |||||
| Issuance of shares in connection with the loan agreement | |||||
| Conversion of convertible promissory notes into common stock in connection with Merger | |||||
| Repurchase of Series B preferred stock | |||||
| Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs | |||||
| Right-of-use assets obtained in exchange for operating lease liabilities | |||||
| Deferred offering costs in accounts payable and accrued expenses | |||||
| Deferred offering cost amortization | |||||
| Receivables from issuance of shares under the sales agreement | |||||
Loading...